This is an aggregated industry headline. Read the full story at FierceBiotech →
Roche bets $700M upfront on Nurix's late-phase BTK degrader to tee up Lilly showdown
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly's Jaypirca in a phase 3 trial.
By FierceBiotech
· Jun 8, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The former quarterback spoke with Fierce Pharma Marketing on teaming up with ARS, his journey with food allerg…
The WeekFierceBiotech ↗
Australian biopharma Clinuvel Pharmaceuticals is moving its headquarters to the U.S.- but up to a fifth of the…
The WeekBriefing
FDA clears GSK’s Jideytro, the company’s first lung cancer drug, marking a swift return on its $10.6B Nuvalent…